Cardiovascular Drugs Market Value Garner US$ 92.3 Bn by 2026

LOS ANGELES, Jan. 30, 2020 /PRNewswire/ --- The Cardiovascular Drugs Market value is poised to garner over US$ 92.3 Bn by 2026 with rising CAGR of around 2.3%.

Acumen Research & Consulting, a global provider of market research studies, in a recently published report titled "Cardiovascular Drugs Market Size, Share and Forecast, 2019 - 2026".

Get Free Download Sample Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1702

North America dominated the global cardiovascular drugs market in the year 2018. The region has experienced the potential growth owing to the presence of cardiovascular drugs companies such as Novartis AG, Bayer AG, Pfizer Inc., Merck and Co. Inc., and Johnson & Johnson, Eli Lilly and Company among others. The presence of a large customer base and increase in development of cardiovascular drugs is additionally accelerating the regional market growth. Moreover, favorable medicare policies, increase in awareness about health, and growing number of hospitals and clinic centers are expected to enhance the market growth in the global cardiovascular drugs market in future growing prevalence of such diseases further expected to raise the demand for cardiovascular drugsin North America. The Europe region is expected to exhibit a second-largest share in the cardiovascular drugsmarket. Stringent government regulations regarding hospital drugs and rapid industrialization, technological advancement in cardiovascular drugs, growing number of medical pharmaciesin countries, such as Germany, the UK, France, Spain, and Italy, are expected to enhance the market growth in the global cardiovascular drugs market during the forecast.

Asia-Pacific region is expected to exhibit highest CAGR in the cardiovascular drugs market. The rapid growth in the urbanization, growing healthcare industry in developing countries, and liberalization of foreign direct investment in the medical sector are the major driving factor for the region in the global market. Moreover, the rising geriatric population and growing awareness regarding treatment options increases its dominance in the global cardiovascular drugs market in future.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/cardiovascular-drugs-market

Growing demand for cardiovascular drugsin various end user applications, growing awareness about cancer treatment across the globe and multi-functionality of cardiovascular drugs are the main drivers for the market growth of the global cardiovascular drugs market over the forecast period. Furthermore, rising investment in research and development of cardiovascular drugs and supportive government initiatives further grows the demand for cardiovascular drugs over the forecast the period. Moreover, technological advancement and increase in the number of applications, and availability of advanced healthcare facilities in developing countries are expected to enhance the market size. This also expected to open investment opportunities in the global market for the manufacturers in the coming years.

However, stringent government regulations and side effects of drugs are expected to hamper the growth of the global cardiovascular drugs market during the forecast period.

Anti-Coagulants segment have dominated the product segment in the year 2018 and the segment is projected to maintain its dominance over the forecast period from 2019 to 2026. Growing prevalence of blood cancer, epiretinal membrane and diabetic retinopathy and escalating demand for drug treatment further expected to drive the demand for the segment. The manufacturers Takeda Pharmaceutical Company Ltd, Otsuka Holdings Co., Ltd, and Novartis AG, are the mainly investing in the development ofanti-coagulants vectors, which expected the lead the market in the coming years.

Related Reports

• Anticoagulants Market - The global market is expected to garner USD 39 billion by 2026 and the market is expected to register CAGR growth over 7.9% during the next eight years.
• Cardiovascular & Soft Tissue Repair Patches Market - The global market is expected to grow at noteworthy CAGR around 8 % throughout the forecast period and reach around US$ 6 billion by 2026.
• Artificial Intelligence for Drug Discovery Market - The global market size is expected to reach around US$ 8,149 Mn by 2026 and is expected to register a CAGR of above 42% over the forecast period 2019 to 2026.

Hospital pharmacies segment dominated the cardiovascular drugs market on the basis of distribution channelin the year 2018. The major factors that are driving the growth of this segment are availability of pharmacies in hospitals and growing number of hospitals across the globe. This expected to enhance the dominance of the hospital segment in the global market over the forecast period.

Some of the leading competitors are Otsuka Holdings Co., Ltd., Gilead Sciences Inc., Sun Pharma Industries, Abbott Laboratories, Novartis AG, Bayer AG, Pfizer Inc., Merck and Co. Inc., and Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Ltd.

Some of the key observations regarding cardiovascular drugs industry include:

• In July 2019, Abbott Medical Optics Inc. announced partnership agreement with Johnson & Johnson, a provider of advanced software solutions for life science R&D. The partnership increases the development of cardiovascular drugsproducts and increases the efficiency of strain development processes.
• In February 2019, Novartis AG signed partnership agreement with Blackstones life science. The partnership focuses on development of cardiovascular drugs and other medical products.
• In November 2018, Novartis AG received approval from European commission for luxturna, a gene therapy to treat patients with a vision loss. The approval enhances the brand identity of the company and enhances its customer base. 
• In January 2017, Novartis AG signed partnership agreement with Caribou. The partnership focuses on innovation and development of drugs and therapy treatment.
• In August 2017, Takeda Pharmaceutical Company Ltd signed partnership agreement with Cardurion Pharmaceuticals. The partnership focuses on development of cardiovascular drugs and next generation medical products.

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1702

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - https://www.acumenresearchandconsulting.com/buy-now/0/1702

If you would like to place an order or have any questions, please feel free to contact at [email protected] | +1-407-915-4157 OR +1-408-900-9135

About Us

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. Among the industries served include aerospace and defense, information and communication technology (ICT), semiconductor and electronics, healthcare and pharmaceuticals, chemicals, advanced materials, banking, finance services and insurance (BFSI), and others.

Our collective industry experience of over 100 years has helped us to offer appropriate market information and our global reach and regional connects ensures appropriate insights into regional markets to guarantee apt delivery of information.

Our regional market intelligence helps our clients to identify potential opportunities and develop growth strategies across regions and countries. Our services are geared towards offering best market research to our clients.

Contact Us:
Mr. Frank Wilson
Acumen Research and Consulting
17890, Castleton St #218, Rowland Heights, CA 91748 United States
Tel: +1-407-915-4157 OR +1-408-900-9135
Email: [email protected] 
Website: https://www.acumenresearchandconsulting.com 

SOURCE Acumen Research and Consulting